Ocular Therapeutix, Inc. (OCUL)

NASDAQ: OCUL · IEX Real-Time Price · USD
3.70
-0.07 (-1.86%)
May 18, 2022 11:18 AM EDT - Market open
Market Cap284.01M
Revenue (ttm)49.37M
Net Income (ttm)-22.22M
Shares Out76.76M
EPS (ttm)-0.98
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume113,315
Open3.68
Previous Close3.77
Day's Range3.65 - 3.77
52-Week Range2.97 - 15.32
Beta1.69
AnalystsBuy
Price Target18.94 (+411.9%)
Earnings DateMay 9, 2022

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing ...

IndustryPharmaceuticals
IPO DateJul 25, 2014
CEOAntony Mattessich
Employees228
Stock ExchangeNASDAQ
Ticker SymbolOCUL
Full Company Profile

Financial Performance

In 2021, OCUL's revenue was $43.52 million, an increase of 150.08% compared to the previous year's $17.40 million. Losses were -$6.55 million, -95.79% less than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is 18.94, which is an increase of 411.89% from the latest price.

Price Target
$18.94
(411.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases a...

1 week ago - Business Wire

Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual M...

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases a...

2 weeks ago - Business Wire

Ocular Therapeutix™ to Report First Quarter 2022 Financial Results

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases...

3 weeks ago - Business Wire

Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Opht...

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases a...

3 weeks ago - Business Wire

Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) ...

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases a...

1 month ago - Business Wire

AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and P...

SHANGHAI , April 12, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, d...

1 month ago - PRNewsWire

Ocular Therapeutix™ to Present at the Cowen 42nd Annual Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

2 months ago - Business Wire

Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0% and 13.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

2 months ago - Business Wire

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

2 months ago - Business Wire

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, E...

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

3 months ago - Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

4 months ago - Business Wire

Ocular Therapeutix's Dexamethasone Ophthalmic Insert Meets Primary Goal In Dry Eye Disease Trial

Ocular Therapeutix Inc (NASDAQ: OCUL) announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The ...

5 months ago - Benzinga

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of D...

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

5 months ago - Business Wire

3 Small-Cap Stocks to Buy Now and Hold for the Long Haul

With valuations under $2 billion at the moment, these stocks have a lot of room to climb.

Other symbols:NNOXRNLX
5 months ago - The Motley Fool

Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

6 months ago - Business Wire

Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

6 months ago - Business Wire

Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 11.54% and 0.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Ocular Therapeutix: Q3 Earnings Insights

Ocular Therapeutix (NASDAQ:OCUL) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

6 months ago - Benzinga

Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

6 months ago - Business Wire

Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement ...

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

6 months ago - Business Wire

Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

6 months ago - Business Wire

Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

6 months ago - Business Wire

Earnings Preview: Ocular Therapeutix (OCUL) Q3 Earnings Expected to Decline

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research